GO
Loading...

Amgen Inc

More

  • Early Glance: Biotechnology companies Monday, 23 Mar 2015 | 10:12 AM ET

    Amgen Inc. fell $3.94 or 2.3 percent, to $166.16. Biogen Idec fell $7.09 or 1.5 percent, to $468.89. Celgene Corp. fell $4.67 or 3.6 percent, to $123.83.

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • Biogen takes aim at Alzheimer's, ALS drugs Monday, 23 Mar 2015 | 6:48 AM ET
    A multiple sclerosis drug manufactured at the Biogen Idec manufacturing plant in Cambridge, Mass.

    Biogen has seen its value quadruple to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions.

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • Final Glance: Biotechnology companies Friday, 20 Mar 2015 | 8:00 PM ET

    Amgen Inc. rose$. 99 or. 6 percent, to $170.10. Biogen Idec rose $42.33 or 9.8 percent, to $475.98. Celgene Corp. rose $3.17 or 2.5 percent, to $128.50.

  • 6 trades on surging biotech sector Friday, 20 Mar 2015 | 6:39 PM ET

    Big-name biotech stocks have been on a tear, but some "Fast Money" traders warned the run may not continue.

  • Midday Glance: Biotechnology companies Friday, 20 Mar 2015 | 1:25 PM ET

    Amgen Inc. rose$. 39 or. 2 percent, to $169.50. Biogen Idec rose $38.60 or 8.9 percent, to $472.25. Celgene Corp. rose $1.36 or 1.1 percent, to $126.69.

  • Early Glance: Biotechnology companies Friday, 20 Mar 2015 | 10:19 AM ET

    Amgen Inc. rose $1.93 or 1.1 percent, to $171.04. Biogen Idec rose $29.86 or 6.9 percent, to $463.51. Celgene Corp. rose $1.29 or 1.0 percent, to $126.62.

  • Cramer: Snap up this incredible opportunity Thursday, 19 Mar 2015 | 6:22 PM ET
    Lab technician handling test tubes

    Jim Cramer can't believe how Esperion Therapeutics stock has shot through the roof! Can it keep going?

  • NEW YORK, March 19- A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients. The judge denied Amgen's request for a preliminary injunction to prevent Novartis' Sandoz unit from launching its copycat drug.

  • Midday Glance: Biotechnology companies Thursday, 19 Mar 2015 | 2:00 PM ET

    Amgen Inc. rose $1.24 or. 7 percent, to $167.78. Biogen Idec rose $7.84 or 1.8 percent, to $435.77. Celgene Corp. rose $2.16 or 1.8 percent, to $124.84.

  • Early Glance: Biotechnology companies Thursday, 19 Mar 2015 | 10:22 AM ET

    Amgen Inc. rose $1.31 or. 8 percent, to $167.85. Biogen Idec rose $9.78 or 2.3 percent, to $437.71. Celgene Corp. rose $2.07 or 1.7 percent, to $124.75.

  • March 16- U.S. stocks rallied on Monday as the U.S. dollar eased back from its recent peak and worries eased about the timing of a Federal Reserve interest rate hike. The S&P healthcare sector led gains in the S&P 500. It jumped 2.2 percent, helped by a 5.7 percent price increase in shares of Amgen to $163.03, following promising data in studies of a new class of...

  • "It's just a little bit of relief from last week's selloff," said Joseph Benanti, managing director, sales and trading of Rosenblatt Securities in New York. The S&P healthcare sector was up 1.9 percent, helped by a 3.6 percent price increase in shares of Amgen to $159.73, following promising data in studies of a new class of cholesterol-reducing drugs.

  • *Empire State manufacturing data miss estimates. "It's just a little bit of relief from last week's selloff," said Joseph Benanti, managing director, sales and trading of Rosenblatt Securities in New York. Until Fed Chair Janet Yellen's statement on Wednesday afternoon, Benanti is expecting light volume.

  • New cholesterol drugs cut heart attack risk in half Monday, 16 Mar 2015 | 8:44 AM ET
    Amgen building in South San Francisco, California.

    Studies of a new class of cholesterol-lowering drugs signal that they can reduce by half the risk of heart attack.

  • An analysis of about 4,500 patients who stayed on treatment for nearly a year after completing earlier trials of Amgen Inc's Repatha, also known as evolocumab, found that 0.95 percent of those given the drug and standard therapy suffered a cardiovascular event, compared with 2.18 percent of the group on standard treatment, which ranged from diet changes to...

  • An analysis of about 4,500 patients who continued treatment for nearly a year after completing earlier trials of Amgen Inc's Repatha, also known as evolocumab, found that 0.95 percent of patients given the drug and standard therapy suffered a cardiovascular event, compared with 2.18 percent of the group receiving standard treatment, which ranged from...

  • These cholesterol drugs stocks are poised to move Friday, 13 Mar 2015 | 3:33 PM ET
    Surgeons performing operation

    Here are the stocks to watch heading out of this weekend's American College of Cardiology conference in San Diego.

  • CVS: Copycat drugs may bring price cuts of 40-50% Thursday, 12 Mar 2015 | 7:14 AM ET

    Copycat biotech drugs in the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, said a top CVS Health exec.